Increasing prevalence of fosfomycin resistance in extended-spectrum-beta-lactamaseproducing escherichia coli urinary isolates (2005-2009-2011);Aumento significativo de la resistencia a fosfomicina en cepas de escherichia coli productoras de β-lactamasas de espectro extendido (BLEE) aisladas de urocultivos (2005-2009-2011)

Revista Espanola de Quimioterapia

Volumn 26, Issue 1, 2013, Pages 43-46

  Rodríguez Avial, Carmen ^a,b   Rodríguez Avial, Iciar ^a,b   Hernández, Elena ^b   Picazo, Juan J ^a,b  

^a UNIVERSIDAD COMPLUTENSE DE MADRID   (Spain)

^b HOSPITAL CLÍNICO SAN CARLOS   (Spain)

Author keywords

Coresistance; ESBL; Escherichia coli; Fosfomycin; UTI

Indexed keywords

BETA LACTAM; CARBAPENEM DERIVATIVE; CIPROFLOXACIN; COLISTIN; COTRIMOXAZOLE; FOSFOMYCIN;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; EXTENDED SPECTRUM BETA LACTAMASE PRODUCING ESCHERICHIA COLI; NONHUMAN; PREVALENCE; URINARY TRACT INFECTION; URINE CULTURE;

ANTI-BACTERIAL AGENTS; BETA-LACTAMASES; CARBAPENEMS; DRUG RESISTANCE, MULTIPLE, BACTERIAL; ESCHERICHIA COLI; ESCHERICHIA COLI INFECTIONS; FOSFOMYCIN; HUMANS; MICROBIAL SENSITIVITY TESTS; PREVALENCE; URINARY TRACT INFECTIONS; URINE;

EID: 84877745147     PISSN: 02143429     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (20)

1. Hoban DJ, Nicolle LE, Hawser S, Bouchillon S, Badal R. Antimicrobial susceptibility of global inpatient urinary tract isolates of Escherichia coli: results from the Study for Monitoring Antimicrobial Resistance Trends (SMART) program: 2009-2010. Diagn Microbiol Infect Dis 2011; 70:507-11.
2. Coque TM, Baquero F, Canton R. Increasing prevalence of ESBL-producing Enterobacteriaceae in Europe. Euro Surveill 2008;13(47).
3. Hernández JR, Pascual A, Cantón R, Martínez-Martínez L, Grupo de Estudio de Infección Hospitalaria (GEIH). Escherichia coli y Klebsiella pneumoniae productores de β-lactamasas de espectro extendido en hospitales españoles (Proyecto GEIH-BLEE 2000). Enferm Infecc Microbiol Clin 2003; 21:77-82.
4. Díaz MA, Hernández JR, Martínez-Martínez L, Rodríguez-Baño J, Pascual A; Grupo de Estudio de Infección Hospitalaria (GEIH). Extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae in Spanish hospitals: 2nd multicenter study (GEIH-BLEE project, 2006). Enferm Infecc Microbiol Clin 2009; 27:503-10.
5. Schultsz C, Geerlings S. Plasmid-mediated resistance in Enterobacteriaceae: changing landscape and implications for therapy. Drugs 2012; 72:1-16.
6. Ríos E, Rodríguez-Avial I, Rodríguez-Avial C, Hernandez E, Picazo JJ. High percentage of resistance to ciprofloxacin and qnrB19 gene identified in urinary isolates of extended-spectrum beta-lactamase-producing Escherichia coli in Madrid, Spain. Diagn Microbiol Infect Dis 2010; 67:380-3.
7. Briales A, Rodríguez-Martínez JM, Velasco C, de Alba PD, Rodríguez-Baño J, Martínez-Martínez L et al. Prevalence of plasmidmediated quinolone resistance determinants qnr and aac(6')-Ib-cr in Escherichia coli and Klebsiella pneumoniae producing extended-spectrum β-lactamases in Spain. Int J Antimicrob Agents 2012; 39:431-4.
8. Meier S, Weber R, Zbinden R, Ruef C, Hasse B. Extended-spectrum -lactamase-producing Gram-negative pathogens in community-acquired urinary tract infections: an increasing challenge for antimicrobial therapy. Infection 2011; 39:333-40.
9. Livermore DM. Current Epidemiology and Growing Resistance of Gram-Negative Pathogens. Korean J Intern Med. 2012; 27:128-42.
10. Falagas ME, Kastoris AC, Kapaskelis AM, Karageorgopoulos DE. Fosfomycin for the treatment of multidrug-resistant, including extended-spectrum β-lactamase producing, Enterobacteriaceae infections: a systematic review. Lancet Infect Dis 2010; 10: 43-50
11. Hernández MS, García JA, Muñoz JL. In vitro activity of fosfomycin against ESBL-producing enterobacteria of urinary origin. Rev Esp Quimioter 2009; 22:25-9.
12. de Cueto M, López L, Hernández JR, Morillo C, Pascual A. In vitro activity of fosfomycin against extended-spectrum-beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae: comparison of susceptibility testing procedures. Antimicrob Agents Chemother 2006; 50:368-70.
13. Ko KS, Suh JY, Peck KR, Lee MY, Oh WS, Kwon KT, et al. In vitro activity of fosfomycin against ciprofloxacin-resistant or extended-spectrum beta-lactamase-producing Escherichia coli isolated from urine and blood. Diagn Microbiol Infect Dis 2007; 58:111-5.
14. Auer S, Wojna A, Hell M. Oral treatment options for ambulatory patients with urinary tract infections caused by extended-Spectrum-β-lactamase-producing Escherichia coli. Antimicrob Agents Chemother 2010; 9:4006-08.
15. Titelman E, Iversen A, Kahlmeter G, Giske CG. Antimicrobial susceptibility to parenteral and oral agents in a largely polyclonal collection of CTX-M-14 and CTX-M-15-producing Escherichia coli and Klebsiella pneumoniae. APMIS 2011; 119:853-63.
16. Clinical and Laboratory standards Institute (CLSI). Performance standards for antimicrobial susceptibility testing; 19th CLSI Informational Suplement. CLSI Document M100-S19, Wayne,PA. CLSI 2009.
17. Grundmann H, Livermore DM, Giske CG, Canton R, Rossolini GM, Campos J, et al. Carbapenem-non-susceptible Enterobacteriaceae in Europe: conclusions from a meeting of national experts. Euro Surveill 2010; 15(46).
18. Rodríguez-Avial C, Rodríguez-Avial I, Merino P, Picazo JJ. Klebsiella pneumoniae: development of a mixed population of carbapenem and tigecycline resistance during antimicrobial therapy in a kidney transplant patient. Clin Microbiol Infect 2012; 18:61-6.
19. Wachino J, Yamane K, Suzuki S, Kimura K, Arakawa Y. Prevalence of fosfomycin resistance among CTX-M-producing Escherichia coli clinical isolates in Japan and identification of novel plasmid-mediated fosfomycin-modifying enzymes. Antimicrob Agents Chemother 2010; 54:3061-64.
20. Oteo J, Bautista V, Lara N, Cuevas O, Arroyo M, Fernández S, et al. Parallel increase in community use of fosfomycin and resistance to fosfomycin in extended-spectrum beta-lactamase (ESBL)-producing Escherichia coli. J Antimicrob Chemother 2010; 65:2459-63.